ARKAY Therapeutics

ARKAY Therapeutics developed a novel beta-cell-centric combination therapy for type 2 diabetes designed to prevent metformin failure and sustain insulin sufficiency. Their lead product, TriGlytza™/RK‑01—a fixed-dose combination of valsartan, celecoxib, and metformin—received FDA IND clearance in mid‑2018. Preclinical studies showed efficacy in animal models with insulin resistance; human proof-of-concept trials were planned but not completed before the asset was sold to Myopharm Limited due to funding constraints during the COVID pandemic. The company’s approach focused on anti-inflammatory mechanisms targeting pancreatic beta cell preservation.